| Prev Close | 29.90 |
| Day Low/High | 29.20 / 30.12 |
| 52 Wk Low/High | 17.20 / 34.29 |
Supernus Pharmaceuticals, Inc. (SUPN)
29.38
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 53.15B |
| Market Cap | 1.59B |
| P/E Ratio | 13.61 |
| Div & Yield | N.A. (N.A) |
Latest News
I'm Placing Selective Bets in a Market That Isn't Deserving of Trust
There are reasons to proceed with extreme caution in the current market, including the possibility that the U.S. won't have a divided government.
2 Promising Biopharma Concerns Not to Overlook
Supernus Pharmaceuticals and Strongbridge Biopharma both recently turned in better-than-expected quarterly results.
On the Lookout for Revenue Rebounds Among Covid-Dinged Biotechs
The early stages of the pandemic hurt sales at many biotech companies, but there are signs that revenue streams are picking back up.
3 Undervalued Stocks That Should Gain Ground in 2020
American Airlines, Supernus Pharmaceuticals and TPI Composites should see their fortunes improve this year.
Putting My Covered Call Strategy to Work With 2 Dinged Biotech Stocks
Sharp drops in Heron Therapeutics and Supernus Pharmaceuticals have presented opportunities to make lemonade out of lemons.
How to Profit From Market Overreactions
A look at Supernus Pharmaceuticals and TPI Composites provides a tutorial on reaping rewards from stocks the market suddenly hates.
3 Names Making the Case That Investing in Small Biotech Is Never Dull
Karyopharm Therapeutics and Pieris Pharmaceuticals are climbing this week on positive news, while Supernus Pharmaceuticals takes a hit.
There's Value In These 2 Small Beaten Down Biotech Stocks
Both stocks have seen some recent insider buying.
10 Speculative Stock Plays in the Biotech Sector
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
3 Profitable Small Biotech Names to Consider
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Three Stocks on the Move
Markets off to a decent start to the trading day with all the major indices up a half hour into trading. Some of the names I have profiled in recent months are on the move early today. Let's take a look at a few of these: T2 Biosystems after posting...
More Tax Reform Winners
One way or another I continue to believe that some sort of tax legislation will be signed before the end of the year.
Market Goes on a 'Buy the Dip' Trip
Stocks slowly recovering from early lows.
There's No Rush for the Exits So Far
There's lots of negativity, but dip buyers are showing up.
Shark Bites: Even Without Health Care Vote, Market's Feeling Better
Broad strength and good tone mark action.
4 Smaller Biotech Names Worth Researching
Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.
4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)
Demographic trends that boosted big gains in prior years haven't gone away.
The Bulls Don't Have Enough Juice for 20,000
But here are 8 stocks that look good to me, right now.
Rev's Forum: Can the Market Find a Second Wind?
This is the time of the year when many moves are made for tax reasons.
Big-Cap Tech Names, Biotechs, Oils Lifting Market
The number of new 12-month highs has climbed to 240.
Small Biotechs on My Shopping List
These small-caps are woefully undervalued after getting shellacked in October.
Going on a Mini Biotech Binge Into the Weekend
Thanks to everyone who contributed to the conversation on the Daily Diary today. It was quite a lively bunch. I wish the market could have held earlier highs, but at least it was a positive end to a volatile trading week and a downright brutal one f...
Supernus Offers Super Small-Cap Potential
Given the biotech's growth prospects and pipeline assets, its shares seem greatly undervalued.
Seeing the Same Old Patterns Ahead of Fed News
Buyers expect a dovish Fed and are still trying to put money to work.
Shark Bites: 5 Stocks I Am Playing in This Choppy Action
Despite the unsettled market, there are still some interesting picks out there.
Looks Like Pessimism Is on the Rise
But there's aggressive capital that wants to be spent.
Risky IPOs: Envivio, Supernus
IPO Desktop President Francis Gaskins believes both Envivio and Supernus are a little risky for investors.
